Trinity Biotech's Enhanced EpiCapture Test Achieves 85% Accuracy in Prostate Cancer Risk Prediction
核心洞察
Trinity Biotech announced successful clinical results for its enhanced EpiCapture (搜索) prostate cancer test, which achieved 85% clinical accuracy (AUC) in a study of 750 patient samples.
The next-generation urine liquid biopsy test incorporates machine learning algorithms that integrate patient ethnicity with DNA biomarkers to provide more accurate, individualized risk prediction scores.
The company plans to commercialize EpiCapture (搜索) as a Laboratory Developed Test through its New York State Department of Health certified diagnostics reference laboratory, marking its strategic entry into precision oncology diagnostics.
Trinity Biotech plc announced successful clinical results for its enhanced EpiCapture (搜索) prostate cancer test, demonstrating 85% clinical accuracy in predicting aggressive prostate cancer risk. The next-generation urine liquid biopsy test incorporates machine learning algorithms that integrate patient ethnicity with DNA biomarkers, addressing a critical gap in oncology diagnostics where performance varies significantly across demographic groups.
Clinical Validation Demonstrates Strong Performance
The enhanced EpiCapture (搜索) test was evaluated in a comprehensive clinical study involving approximately 750 patient samples, representing a substantially larger and more ethnically diverse cohort than previous studies. The study was conducted independently by a specialist bioinformatics research partner to ensure rigorous validation of the diagnostic performance.
Results indicate the new version delivers clinical accuracy (Area Under the Curve, AUC) of 85%, a level considered strong and clinically useful within the oncology diagnostics field. Dr. Antoinette Perry, Associate Professor in Cell & Molecular Biology at University College Dublin, noted that "the results of this multi-centre study demonstrate strong performance and establish the technology as a first-in-field biomarker test to incorporate ethnicity as a key variable within its predictive algorithm."
Addressing Critical Healthcare Barriers
EpiCapture (搜索) offers a less invasive alternative to traditional diagnostic methods for assessing high-grade prostate cancer risk. Current approaches, including high-resolution MRI scans that are often costly and limited in availability, and needle biopsies that may expose patients to infection risk and other complications, present significant barriers to early and accessible detection.
Prostate cancer represents a substantial healthcare burden, affecting approximately 1 in 8 men during their lifetime in the U.S., with national expenditures for prostate cancer care recently estimated to exceed $20 billion annually. The ability to accurately monitor prostate cancer progression is critical, as the disease can often be slow-growing, and unnecessary invasive interventions can lead to significant complications.
Strategic Market Entry and Commercialization
Trinity Biotech plans to commercialize the EpiCapture (搜索) test as a proprietary Laboratory Developed Test (LDT) through its New York State Department of Health certified diagnostics reference laboratory. This strategy allows for rapid roll-out of the precision oncology testing service to patients across the U.S.
EpiCapture (搜索) marks Trinity Biotech's first entry into the precision oncology diagnostics market, representing a significant milestone in the company's strategic evolution toward precision medicine applications. John Gillard, President and Chief Executive Officer of Trinity Biotech, commented: "The enhanced EpiCapture test represents a major step forward for prostate cancer risk prediction and underscores further significant progress in our broader innovation agenda. This is a strong example of how we are expanding into precision medicine and building a portfolio of advanced, multimodal, data driven diagnostics."
Addressing Ethnic Disparities in Cancer Care
The enhanced test specifically addresses a well-documented challenge in oncology diagnostics: meaningful performance variation across different demographic and ethnic groups. Prostate cancer incidence and outcomes vary significantly across different geographic and ethnic populations, yet the biological drivers underlying these differences remain incompletely understood.
The findings from this clinical study will be submitted for publication in a peer-reviewed oncology journal, supporting the scientific validation of this first-in-field approach to incorporating ethnicity as a key variable within prostate cancer risk prediction algorithms.